Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Extra Strength Tylenol Cap Warning Prompts Label Reading

This article was originally published in The Pink Sheet Daily

Executive Summary

Beginning in October, bottle caps of Extra Strength Tylenol will warn consumers the product contains acetaminophen and they should always read the label. The warning is the third element to highlight the ingredient on Extra Strength Tylenol but the redundancy may be necessary because consumers do not read labels.

You may also be interested in...



Cold Indication For Antihistamines Targeted In Regulatory Agenda

The latest regulatory agenda says FDA targets issuing proposed rules on OTC antimicrobial hand wash products in February and leave-on antiseptics in July, and in February to finalize an OTC monograph for oral bronchodilator in combination with expectorants or oral nasal decongestants.

Acetaminophen Overdose Risk Persists Despite Label Changes – Study

Many consumers do not closely read OTC painkiller labels and often do not adhere to package or label instructions, researchers say. Many likely are unaware of or ignore label changes industry voluntarily made and FDA ordered to reduce the risk of liver toxicity due to unintentional overdose.

McNeil Lowers Recommended Maximum Dose For Extra Strength Tylenol

McNeil Consumer Healthcare lowers the maximum daily dose indicated on labels of Extra Strength Tylenol, the first in a series of dosing changes for the firm’s acetaminophen-containing products.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel